在缺乏临床数据时PSMA PET/CT的观察者间一致性仍高
研究纳入60例接受68Ga-PSMA-11 PET/CT的前列腺癌男性,3名独立阅片者先后在遮蔽与显示临床资料条件下按PSMA-RADS 1.0评分,总体扫描结果与RADS评分的一致性为优,显示临床资料后仅少数病例改判,提示标准化框架在无患者信息时仍可指导判读。
要点
- 总体扫描结果、淋巴结转移、器官受累及放射性配体治疗指征的ICC分别为0.85、0.89、0.82、0.94,均为优。
- 总体RADS评分ICC为0.91,靶病灶层面各部位ICC为0.48至0.81,一致性为尚可至优。
- 显示临床资料后靶病灶层面RADS评分仅8例次改判,主要原因为提供PSA水平。
核心结论
- 应用PSMA-RADS时观察者间一致性为尚可至优,提供临床数据后仅少见相关改判,即使缺乏患者信息标准化框架仍可为PSMA PET判读提供指导。
研究设计与样本
- 纳入60例均接受68Ga-PSMA-11 PET/CT的前列腺癌男性,由3名独立且有经验的阅片者判读。
- 阅片者报告总体扫描参数并按PSMA-RADS 1.0对靶病灶及总体扫描层面评分。
- 第一次阅片时遮蔽所有相关临床信息,第二次阅片时显示相关患者特征以评估临床信息对判读的影响。
- 采用组内相关系数(ICC)及95%CI评价一致性,并按Cicchetti标准分级:0.4-0.59尚可、0.6-0.74良、0.75-1优。
主要发现
- 总体扫描结果ICC为0.85(95%CI 0.76-0.90),淋巴结转移ICC为0.89(95%CI 0.83-0.93),器官受累ICC为0.82(95%CI 0.72-0.89),放射性配体治疗指征ICC为0.94(95%CI 0.90-0.96)。
- 总体RADS评分ICC为0.91(95%CI 0.96-09.4),原文此处写作0.96-09.4,按上下文应为0.94。
- 3名观察者共选择251个不同靶病灶,其中73个为3名阅片者共同选择。
- 靶病灶层面RADS一致性:全部病灶ICC为0.78(95%CI 0.67-0.85),淋巴结ICC为0.81(95%CI 0.63-0.92),骨骼ICC为0.55(95%CI 0-0.84),前列腺ICC为0.48(95%CI 0.17-0.78)。
- 第二次阅片显示患者特征后,靶病灶层面RADS评分仅少量修改(总体n=8):阅片者1和2各为3/60(5%),阅片者3为2/60(3.3%);改判主要原因(主要为上调分期)为提供的PSA水平信息(4/8,50%)。
关键数值与推荐
- PSMA-RADS 1.0用于靶病灶及总体扫描层面评分。
- 一致性按Cicchetti分级:ICC 0.4-0.59为尚可、0.6-0.74为良、0.75-1为优。
临床怎么用
- 作者认为,即使缺乏患者信息,标准化框架仍可为PSMA PET判读提供指导。
- 作者认为,这些发现可能对患者详情无法在判读时获取的高通量繁忙PET实践、或阅片者对临床数据设盲的临床试验或中心判读具有意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recommended by current guidelines, prostate-specific membrane antigen (PSMA)-directed PET/CT is increasingly used in men with prostate cancer (PC). We aimed to provide concordance rates using the PSMA reporting and data system (RADS) for scan interpretation and also determine whether such agreement rates are affected by available patient characteristics at time of scan. PATIENTS AND METHODS: Sixty men with PC, who all underwent 68Ga-PSMA-11 PET/CT, were included. Three independent, experienced readers indicated general scan parameters (including overall scan result, organ or lymph node [LN] involvement, and appropriateness of radioligand therapy). Applying PSMA-RADS 1.0, observers also had to conduct RADS scoring on a target lesion (TL) and overall scan level. During the first read, observers were masked to all relevant clinical information, whereas on a second read, relevant patient characteristics were displayed, thereby allowing for determination of impact of available clinical information for scan interpretation. We used intraclass correlation coefficients (ICCs; with 95% confidence intervals [CIs]), which were then rated according to Cicchetti (0.4-0.59 fair, 0.6-0.74 good, and 0.75-1 excellent agreement). RESULTS: For general parameters, agreement rates were excellent, including an overall scan result (ICC, 0.85; 95% CI, 0.76-0.90), LN metastases (ICC, 0.89; 95% CI, 0.83-0.93), organ involvement (ICC, 0.82; 95% CI, 0.72-0.89), and indication for radioligand therapy (ICC, 0.94; 95% CI, 0.90-0.96). Overall RADS scoring was also excellent with an ICC of 0.91 (95% CI, 0.96-09.4). On a TL-based level, 251 different lesions were selected by the 3 observers (with 73 chosen by all 3 readers). RADS-based concordance rates were fair to excellent: all lesions, ICC of 0.78 (95% CI, 0.67-0.85); LN, ICC of 0.81 (95% CI, 0.63-0.92); skeleton, ICC of 0.55 (95% CI, 0-0.84); and prostate, ICC of 0.48 (95% CI, 0.17-0.78). When performing a second read displaying patient's characteristics, there were only minor modifications to the previously applied RADS scoring on a TL-based level (overall, n = 8): each reader 1 and 2 in 3/60 (5%) instances, and reader 3 in 2/60 (3.3%) instances. The main reason for recategorization (mainly upstaging) was provided information on PSA levels (4/8, 50%). CONCLUSIONS: Applying PSMA-RADS, concordance rates were fair to excellent, whereas relevant modifications were rarely observed after providing clinical data. As such, even in the absence of patient information, standardized frameworks still provide guidance for reading PSMA PETs. Those findings may have implications for a high throughput in a busy PET practice, where patient details cannot always be retrieved at time of scan interpretation or in the context of clinical trials or central reviews in which readers may be blinded to clinical data.
引用
- Bundschuh RA, Lütje S, Bundschuh L, et al. High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data. Clin Nucl Med. 2023. PMID: 36723879. doi:10.1097/RLU.0000000000004524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。